Grant: Engage Plus Grants Program
University of Guelph
$11,910.00
Optimization of scalable chromatography-based purification methods utilizing NatriFlo HD-Q membrane technology for downstream processing of viral vaccines and viral vectors
EF 2017-18
Résumé
Viruses engineered to express antigens to promote a protective immune response against a particular pathogen(vaccine), or to deliver a therapeutic gene (gene therapy) or to treat cancer (oncolytic virotherapy) are essentialtools used in the prevention and treatment of diseases in humans and animals. However, a considerableimpediment to the use of viruses as vaccines or therapeutic agents is the availability of efficient, scalablepurification systems. The goal of this project is to build upon the process development expertise acquiredduring our initial NSERC Engage funded collaboration with Natrix Separations, in which we successfullydeveloped a process for purifying high titer, clinical grade Newcastle Disease virus, and apply this knowledgeto the design, optimization and dissemination of detailed process purification protocols for production of hightiter, clinical grade viral vaccines and gene transfer vectors using NatriFlo HD-Q membrane technology. NatrixSeparations is a leading supplier of high performance, single use and multi-cycle chromatography products tothe life science markets. Their membrane chromatography columns are used in a variety of applicationsincluding the separation and purification of peptides, proteins, nucleic acids, and monoclonal antibodies. Togrow their business, Natrix is seeking to broaden their patented separation technology platform to includepurification of clinical grade viral vaccines/vectors and oncolytic viruses for use in humans and animals. WhileNatrix has the chromatographic devices and process development expertise, they do not have the infrastructure(CL2 lab and animal facilities, access to viruses) or the virology expertise necessary to conduct theseexperiments. Therefore, it is absolutely critical that Natrix partner with an academic virology lab to developvirus-specific purification processes and evaluate the activity and purity of the final product in an animalmodel. Indeed, that was the premise of our initial NSERC Engage grant. Due to the tremendous success of thiscollaboration, we are now applying for funding to develop and test anion exchange and affinitychromatography-based purification processes for a variety of clinically relevant viral vaccines and viral vectors.
Programme
Engage Plus Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
515222-2017
Name nom
Wootton, KSarah
Department département
Pathobiology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
11910
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Partie
1
Nb partie
1
Application title
Optimization of scalable chromatography-based purification methods utilizing NatriFlo HD-Q
membrane technology for downstream processing of viral vaccines and viral vectors
Keyword
NSERC
Application summary
Viruses engineered to express antigens to promote a protective immune response against a particular pathogen(vaccine), or to deliver a therapeutic gene (gene therapy) or to treat cancer (oncolytic virotherapy) are essentialtools used in the prevention and treatment of diseases in humans and animals. However, a considerableimpediment to the use of viruses as vaccines or therapeutic agents is the availability of efficient, scalablepurification systems. The goal of this project is to build upon the process development expertise acquiredduring our initial NSERC Engage funded collaboration with Natrix Separations, in which we successfullydeveloped a process for purifying high titer, clinical grade Newcastle Disease virus, and apply this knowledgeto the design, optimization and dissemination of detailed process purification protocols for production of hightiter, clinical grade viral vaccines and gene transfer vectors using NatriFlo HD-Q membrane technology. NatrixSeparations is a leading supplier of high performance, single use and multi-cycle chromatography products tothe life science markets. Their membrane chromatography columns are used in a variety of applicationsincluding the separation and purification of peptides, proteins, nucleic acids, and monoclonal antibodies. Togrow their business, Natrix is seeking to broaden their patented separation technology platform to includepurification of clinical grade viral vaccines/vectors and oncolytic viruses for use in humans and animals. WhileNatrix has the chromatographic devices and process development expertise, they do not have the infrastructure(CL2 lab and animal facilities, access to viruses) or the virology expertise necessary to conduct theseexperiments. Therefore, it is absolutely critical that Natrix partner with an academic virology lab to developvirus-specific purification processes and evaluate the activity and purity of the final product in an animalmodel. Indeed, that was the premise of our initial NSERC Engage grant. Due to the tremendous success of thiscollaboration, we are now applying for funding to develop and test anion exchange and affinitychromatography-based purification processes for a variety of clinically relevant viral vaccines and viral vectors.